Gapping up
News:
- HT +55.4% (acquired by KSL Capital Partners; common shareholders to receive $10.00/share in cash a 60% premium to prior closing price)
- HE +34.1% (Provides Update on Lahaina Fires Response)
- RPT +14.9% (Kimco Realty (KIM) to acquire RPT Realty in all-stock transaction)
- XPEV +5.6% (to expand in A-class Smart EV Segment through strategic partnership with DiDi)
- JBL +5.6% (enters into preliminary agreement relating to divest Mobility business )
- MMM +5.4% (to pay $5.5 bln to resolve military earplug lawsuits)
- HZNP +5.2% (FTC files motion to withdraw matter from adjudication regarding Amgen (AMGN) deal for HZNP)
- BSX +4.9% (reports ADVENT study of the FARAPULSE Pulsed Field Ablation System meets primary efficacy and safety endpoints)
- VSTM +4.9% (enters discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers)
- BBIO +4.8% (presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress)
- ESPR +4.3% (presents two CLEAR outcomes study late-breakers at European Society of Cardiology Congress 2023)
- XIN +3.5% (announces progress achievement in debt restructuring)
- NVAX +2.7% (President Biden will request funding for next round of coronavirus vaccines)
- NNDM +2.1% (resumes its share repurchase plan immediately)
- ANIP +2% (following FDA approval and launch of estradiol gel)
- TGLS +1.8% (to more than double addressable market with strategic entry into vinyl windows)
- LEU +1.4% (Centrus Energy and Oklo sign MOU for fuel components and power procurement)
- ACGL +1.2% (positive Barron's article)
- BNTX +1.2% (President Biden will request funding for next round of coronavirus vaccines)
- AKRO +1.1% (to Report Results of Phase 2b SYMMETRY Study in October 2023)
- FSR +1% (announced that it has launched in three new European markets)
Analyst comments:
- AKBA +9.6% (upgraded to Buy from Neutral at H.C. Wainwright)
- MCW +6.4% (upgraded to Overweight from Neutral at Piper Sandler)
- UGI +2.7% (upgraded to Overweight from Equal Weight at Wells Fargo)
- APPF +2% (upgraded to Outperform from Mkt Perform at William Blair)
- MTSI +1.9% (upgraded to Buy from Hold at The Benchmark Company)
- CHD +1.7% (upgraded to Buy from Hold at Truist)
- ZBH +1.2% (upgraded to Buy from Neutral at BTIG Research)
- FWRD +0.8% (upgraded to Peer Perform from Underperform at Wolfe Research)